What to Expect From Baxter International’s Next Quarterly Earnings Report

Core Insights - Baxter International Inc. is a global healthcare technology company with a market cap of $11.8 billion, specializing in essential hospital and renal-care products [1] - The company is expected to announce its fiscal third-quarter earnings on October 30, with analysts predicting a profit of $0.60 per share, a 25% decrease from the previous year's $0.80 per share [2] - Analysts forecast an EPS of $2.45 for the current year, representing a 29.6% increase from $1.89 in fiscal 2024, and a further rise to $2.60 in FY2026 [3] Stock Performance - BAX stock has declined by 37.3% over the past year, underperforming the S&P 500 Index's 16.9% gain and the Health Care Select Sector SPDR Fund's 2.3% dip [4] - Recent pressures on BAX shares include a 3% drop on October 10 due to market-wide sell-offs linked to trade tensions with China [5] - A 3.7% decline occurred on September 25 following a U.S. Commerce Department investigation into medical equipment imports, raising concerns about potential tariffs and supply chain disruptions [6] Analyst Ratings - The consensus opinion on BAX stock is neutral, with an overall "Hold" rating from 16 analysts: three recommend "Strong Buy," twelve suggest "Hold," and one advises "Moderate Sell" [7] - The average analyst price target for BAX is $27.71, indicating a potential upside of 20.4% from current levels [7]